Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage "SHRINC"


Phase 2 Results N/A

Summary of Purpose

Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes. In an effort to develop a new treatment for ICH, this research focuses on a different aspect of ICH treatment which has not yet been evaluated: enhancing absorption of the blood clot with medication.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 1 October 2015.

1 Mar 2009 21 Jan 2009 1 Apr 2013 1 Nov 2013 1 Oct 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment